Literature DB >> 12039445

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.

David M Stern1, Shi Du Yan, Shi Fang Yan, Ann Marie Schmidt.   

Abstract

Receptor for Advanced Glycation Endproducts (RAGE) is a multiligand member of the immunoglobulin superfamily of cell surface molecules with a diverse repertoire of ligands. These ligands include products of nonenzymatic glycation, the Advanced Glycation Endproducts (AGEs, enriched in the diabetic milieu), members of the S100/calgranulin family of proinflammatory mediators, beta-sheet fibrillar structures (characteristic of amyloid) and amphoterin (present at high levels in the tumor bed). Ligation of RAGE by its ligands upregulates expression of the receptor and triggers an ascending spiral of cellular perturbation due to sustained RAGE-mediated cellular activation. For example, in the setting of diabetes, a vascular environment rich in AGEs and S100/calgranulins accelerates atherogenesis in murine models, and this can be blocked by intercepting the interaction of ligands with RAGE. While RAGE is certainly not the cause of diabetes, it functions as a progression factor driving cellular dysfunction underlying the development of diabetic complications as the microenvironment becomes enriched in its ligands. Though further studies will be required to determine the importance of RAGE-mediated cellular activation to human chronic diseases, it represents a novel receptor-ligand system potentially impacting on a range of pathophysiologic conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039445     DOI: 10.1016/s0047-6374(01)00366-9

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  66 in total

1.  The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant.

Authors:  Sun Jin Park; Torsten Kleffmann; Paul A Hessian
Journal:  J Biol Chem       Date:  2011-04-21       Impact factor: 5.157

2.  Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.

Authors:  Hongliang Zong; Angelina Madden; Micheal Ward; Mark H Mooney; Christopher T Elliott; Alan W Stitt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 4.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

5.  Genetic analysis of advanced glycation end products in the DHS MIND study.

Authors:  Jeremy N Adams; Laura M Raffield; Susan E Martelle; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Amanda J Cox; Donald W Bowden
Journal:  Gene       Date:  2016-02-23       Impact factor: 3.688

6.  Alterations in intervertebral disc composition, matrix homeostasis and biomechanical behavior in the UCD-T2DM rat model of type 2 diabetes.

Authors:  Aaron J Fields; Britta Berg-Johansen; Lionel N Metz; Stephanie Miller; Brandan La; Ellen C Liebenberg; Dezba G Coughlin; James L Graham; Kimber L Stanhope; Peter J Havel; Jeffrey C Lotz
Journal:  J Orthop Res       Date:  2015-03-02       Impact factor: 3.494

Review 7.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

8.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

9.  Tetrahydroindenoindole inhibits the progression of diabetes in mice.

Authors:  Howard G Shertzer; Scott N Schneider; Eric L Kendig; Deborah J Clegg; David A D'Alessio; Elisabet Johansson; Mary Beth Genter
Journal:  Chem Biol Interact       Date:  2008-09-07       Impact factor: 5.192

Review 10.  Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.

Authors:  Inge A M van den Oever; Hennie G Raterman; Mike T Nurmohamed; Suat Simsek
Journal:  Mediators Inflamm       Date:  2010-06-15       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.